This episode Don and John thought they would talk about something near and dear to our hearts here at KCAS – Antibody-Drug Conjugates. Increasingly we’ve all experienced talk about ADCs everywhere being approved and for various conditions – mostly oncology (drugs used in the treatment of cancer). And of course the point of an ADC is to use the ability of the antibody to deliver an otherwise very toxic drug to the area of interest as safely as possible. KCAS has supported multiple ADC studies both in the Pharmaceutical and Biopharmaceutical devisions, so Dom and John were really excited about this one!


To view/listen to the episode of “the Weekly Bioanalysis” click the play button below!


You can always find the latest episode of “The Weekly Bioanalysis” here,

but you can also subscribe to the podcast on Apple Podcasts or any of the major podcast distribution channels!


We would love to hear from you about questions you have from our podcast – or even feedback on how we could improve it!

Please use the form below to reach out to us.

Scroll to Top